Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Sponsor: The First Affiliated Hospital of Zhengzhou University
Summary
Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
208
Start Date
2024-08-15
Completion Date
2027-08-31
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
cadonilizumab combined with neoadjuvant radiochemotherapy
Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.
neoadjuvant radiochemotherapy
Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.
Locations (1)
the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China